SQUAWK/NEWS
Account
Theme
Account
Menu
Live NewsCategoriesequity

Sunshine Biopharma, Inc. (SBFM) News

Follow Sunshine Biopharma, Inc. (SBFM) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 18 public stories across 13 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.

Symbol SBFM Asset equity Sector Markets 90 days 12 Last 2.335 Updated Nov 09, 2026, 12:02 PM UTC Open live news feed Open SBFM chart & news
M SBFM Q3'26 earnings preview cites $9.60 million revenue estimate SBFM is set to announce Q3'26 results November 10; revenue is estimated at $9.60 million and EPS at (3.40) USD. The release time is not specified. EQUITY | Nov 09, 2026, 12:02 PM UTC M Sunshine Biopharma Sets 1-for-20 Reverse Split to Regain Nasdaq Compliance The split takes effect at the market open on Oct. 26, 2026, reducing outstanding shares from 15,219,383 to approximately 760,969. EQUITY | Oct 22, 2026, 01:04 PM UTC H Crude Oil Gains 5%; PepsiCo Posts Upbeat Q3 Earnings U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling over 150 points on Thursday. The Dow traded down 0.39% to 50,978.59 while the NASDAQ declined 0.61% to 27,371.84. The S&P 500 also fell, LIVE | Oct 08, 2026, 04:03 PM UTC L Sunshine Biopharma Inc. (SBFM) Launches Generic Ondansetron in Canada Sunshine Biopharma Inc. launched generic Ondansetron 4mg and 8mg film—coated tablets in Canada via Nora Pharma, expanding its oncology supportive care lineup.Material DetailsContext by AI AnalystThis is a mid-cycle portf NEWS | Sep 24, 2026, 01:01 PM UTC L Sunshine Biopharma Launches Generic Zofran(R) in Canada, Expanding Oncology Supportive Care Portfolio FORT LAUDERDALE, FL / / September 24, 2026 / Sunshine Biopharma Inc. NASDAQ:SBFM (the "Company"), a leading pharmaceutical company specializing in generic and specialty prescription medications including drugs in the are NEWS | Sep 24, 2026, 01:01 PM UTC L SBFM - Sunshine Biopharma Launches Generic Zofran(R) in Canada, Expanding Oncology Supportive Care Portfolio SBFM - Sunshine Biopharma Launches Generic Zofran(R) in Canada, Expanding Oncology Supportive Care Portfolio NEWS | Sep 24, 2026, 01:00 PM UTC L SBFM - Sunshine Biopharma Advances Lead Coronavirus Drug Candidate into IND-Enabling Studies SBFM - Sunshine Biopharma Advances Lead Coronavirus Drug Candidate into IND-Enabling Studies NEWS | Sep 16, 2026, 01:00 PM UTC H EXCLUSIVE: Sunshine Biopharma Advances 'Differentiated Antiviral Candidate' to IND-Enabling Studies Sunshine Biopharma Inc. (NASDAQ: SBFM ) on Wednesday announced it advanced its lead Coronavirus drug candidate into IND-enabling studies. The company had previously published laboratory results on its library of compound LIVE | Sep 16, 2026, 12:31 PM UTC M Sunshine Biopharma: Health Canada approves atenolol for cardiovascular conditions Sunshine Biopharma says Health Canada approved atenolol for treating cardiovascular conditions. EQUITY | Aug 31, 2026, 02:31 PM UTC L Dr. Andrew Keller to Leave Sunshine Biopharma Board at Term End Dr. Andrew Keller to Leave Sunshine Biopharma Board at Term End EQUITY | Aug 28, 2026, 08:15 PM UTC L Sunshine Biopharma advances mRNA cancer vaccine strategy for lung cancer SBFM says its in vivo work shows tumor suppression with K1.1 mRNA and it is advancing a novel mRNA vaccine strategy for lung cancer. EQUITY | Aug 26, 2026, 01:00 PM UTC L Sunshine Biopharma advances K1.1 mRNA cancer-vaccine strategy Sunshine Biopharma says it has reported in vivo tumor suppression with K1.1 mRNA and advanced a novel mRNA-cancer vaccine strategy for lung cancer. EQUITY | Aug 26, 2026, 01:00 PM UTC L Sunshine Biopharma gets Canadian approval for enalapril Sunshine Biopharma (SBFM) says it received Canadian regulatory approval for enalapril, positioning the company to expand within a stated $25.94 billion global anti-hypertensive drug market. REGULATION | Aug 19, 2026, 01:00 PM UTC L SBFM - Sunshine Biopharma Enters the $2.8 Billion Global Dienogest Market with Canadian Regulatory Approval SBFM - Sunshine Biopharma Enters the $2.8 Billion Global Dienogest Market with Canadian Regulatory Approval EQUITY | Aug 04, 2026, 01:00 PM UTC L SBFM - Health Canada Approves Sunshine Biopharma's Ondansetron for Treatment of Chemotherapy-Induced Nausea and Vomiting SBFM - Health Canada Approves Sunshine Biopharma's Ondansetron for Treatment of Chemotherapy-Induced Nausea and Vomiting EQUITY | Jul 28, 2026, 12:00 PM UTC L SBFM Sunshine Biopharma - enters at-the-market sales agreement with aegis capital for up to $4M - SEC filing SBFM Sunshine Biopharma - enters at-the-market sales agreement with aegis capital for up to $4M - SEC filing REGULATION | Jul 20, 2026, 08:29 PM UTC M SBFM Gets Canada Approval Sunshine Biopharma announces approval of generic Anastrozole tablets for Canadian market EQUITY | Jun 25, 2026, 12:04 PM UTC M SBFM Receives Approval Sunshine Biopharma receives Canadian regulatory approval for generic Arimidex EQUITY | Jun 25, 2026, 12:01 PM UTC